Compare JPMorgan Chase & Co (JPM) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Novo Nordisk A/S — how do they compare? JPMorgan Chase & Co trades at $344.89 (market cap $900.78B), while Novo Nordisk A/S trades at $49.34 (market cap $220.53B). The key difference: JPMorgan Chase & Co is far larger — about 4.1× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| JPM | NVO | |
|---|---|---|
Market Cap | $900.78B | $220.53B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $346.91 | $71.70 |
52-Week Low | $282.84 | $35.29 |
Dividend Yield | 1.77% | 3.63% |
Enterprise Value | — | $239.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $345.10, up 1.17% on the day, with strong technical momentum as the stock approaches resistance at $347. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026, with revenue growing to $181.85 billion in 2025. Analyst sentiment remains positive with a consensus price target of $372.73, representing 8% upside potential from current levels.
JPMorgan demonstrates solid fundamentals with a reasonable P/E of 14.52 and strong net income margin of 33.4%. However, negative operating cash flow of -$147.78 billion in 2025 and geopolitical risks highlighted by CEO Jamie Dimon present headwinds. The stock offers value for long-term investors but faces near-term volatility from earnings uncertainty and macroeconomic concerns.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
